Phio Pharmaceuticals Corp. (PHIO)
Data as of , from SEC Form 4 filings.
Net insider buying (90d)Watch PHIO
See up to 3 months of PHIO. The 7-day demo opens the 1M and 3M ranges and puts PHIO on your watchlist.
Start 7-day demoLatest PHIO insider trades
About Phio Pharmaceuticals Corp. (PHIO)
Phio Pharmaceuticals Corp. files with the SEC under CIK 0001533040 and is classified as pharmaceutical preparations. We track it alongside the rest of the Health Care sector.
PHIO Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 7 | 55,500 | $59K |
| Grant or award | 3 | 525,000 | |
| Tax withholding / forfeiture | 2 | 81,438 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
PHIO insider transactions (Form 4)
3232 Form 4 filings on record, the earliest from May 21, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Ronald Todd Plott - Director | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.03 | $5K | |
| Ronald Todd Plott - Director | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.04 | $5K | |
| Lisa Cabott Carson - Officer | Grant or award | Common Stock, $.0001 par value | 108,000 footnote F1 | $0.00 | - | |
| ||||||
| Robert J. Bitterman - Officer | Grant or award | Common Stock, $.0001 par value | 400,000 footnote F1 | $0.00 | - | |
| ||||||
| Ronald Todd Plott - Director | Grant or award | Common Stock, $.0001 par value | 17,000 footnote F1 | $0.00 | - | |
| ||||||
 Patricia A. Bradford - Director | Open-market purchase | Common Stock, $.0001 par value | 6,500 | $1.01 | $7K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 2,000 | $1.03 | $2K | |
| Patricia A. Bradford - Director | Open-market purchase | Common Stock, $.0001 par value | 12,000 | $1.03 | $12K | |
| Lisa Cabott Carson - Officer | Tax withholding / forfeiture | Common Stock, $.0001 par value | 12,888 | $1.03 | $13K | |
| Robert J. Bitterman - Officer | Tax withholding / forfeiture | Common Stock, $.0001 par value | 68,550 | $1.03 | $71K | |
| Ronald Todd Plott - Director | Open-market purchase | Common Stock, $.0001 par value | 15,000 | $1.14 | $17K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 10,000 | $1.06 | $11K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 10,000 | $0.99 | $10K | |
 Curtis Lockshin - Director | Grant or award | Common Stock, $.0001 par value | 16,600 footnote F1 | $0.00 | - | |
| ||||||
| Jonathan E. Freeman - Director | Grant or award | Common Stock, $.0001 par value | 16,600 footnote F1 | $0.00 | - | |
| ||||||
| David H. Deming - Director | Grant or award | Common Stock, $.0001 par value | 23,800 footnote F1 | $0.00 | - | |
| ||||||
| Lisa Cabott Carson - Officer | Grant or award | Common Stock, $.0001 par value | 47,000 footnote F1 | $0.00 | - | |
| ||||||
| Patricia A. Bradford - Director | Grant or award | Common Stock, $.0001 par value | 18,500 footnote F1 | $0.00 | - | |
| ||||||
| Robert J. Bitterman - Officer | Grant or award | Common Stock, $.0001 par value | 120,000 footnote F1 | $0.00 | - | |
| ||||||
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.03 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.02 | $5K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.14 | $6K | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $.0001 par value | 5,000 | $1.27 | $6K | |
| David H. Deming - Director | Grant or award | Common Stock, $.0001 par value | 14,000 | $0.00 | - | |
| Jonathan E. Freeman - Director | Grant or award | Common Stock, $.0001 par value | 14,700 | $0.00 | - | |
| Lisa Cabott Carson - Officer | Grant or award | Common Stock, $.0001 par value | 47,000 | $0.00 | - | |
| Robert L. Ferrara - Director | Grant or award | Common Stock, $.0001 par value | 23,100 | $0.00 | - | |
| Curtis Lockshin - Director | Grant or award | Common Stock, $.0001 par value | 16,200 | $0.00 | - | |
| Patricia A. Bradford - Director | Grant or award | Common Stock, $.0001 par value | 18,800 | $0.00 | - | |
| Robert J. Bitterman - Officer | Tax withholding / forfeiture | Common Stock, $.0001 par value | 4,111 | $2.32 | $10K | |
| Robert J. Bitterman - Officer | Grant or award | Common Stock, $.0001 par value | 250,000 | $0.00 | - | |
| Robert J. Bitterman - Officer | Open-market purchase | Common Stock, $0.0001 par value | 2,000 | $2.42 | $5K | |
Item 8.01, 9.01
Item 5.02, 5.07, 9.01
Item 8.01, 9.01
Item 2.02, 9.01
PHIO insider trading FAQ
What is the latest insider trade for PHIO?
Phio Pharmaceuticals Corp. (PHIO) had 11 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for PHIO runs to 32 Form 4 filings, the earliest from 2025-05-21. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying PHIO stock?
7 insider purchases of PHIO were filed in the last 90 days, totaling $59K.
How many insiders are selling PHIO stock?
No insider sales of PHIO were filed in the last 90 days.
Where can I see PHIO SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects PHIO Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Ronald Todd Plott view on EDGAR
- - Lisa Cabott Carson view on EDGAR
- - Robert J. Bitterman view on EDGAR
- - Ronald Todd Plott view on EDGAR
- - Patricia A. Bradford view on EDGAR
- - Robert J. Bitterman view on EDGAR
- - Patricia A. Bradford view on EDGAR
- - Lisa Cabott Carson view on EDGAR
- - Robert J. Bitterman view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where PHIO's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow PHIO with a 7-day demo
- PHIO on your watchlist
- Every PHIO Form 4 filing on record
- Up to 3 months of PHIO price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
